<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00959192</url>
  </required_header>
  <id_info>
    <org_study_id>3134K1-2206</org_study_id>
    <secondary_id>B2571009</secondary_id>
    <nct_id>NCT00959192</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease</brief_title>
  <official_title>Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 Withqs-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, and immunogenicity of
      ACC-001, an investigational vaccine, in subjects with mild to moderate Alzheimer's disease in
      Japan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-emergent Adverse Events (AEs) by Severity</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>Number of participants who experienced mild, moderate, or severe AEs (mild = does not interfere with subject's usual function; moderate = interferes to some extent with subject's usual function; severe = interferes significantly with subject's usual function)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Brain Abnormalities in Magnetic Resonance Imaging (MRI) Data</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>Number of participants with brain abnormalities in MRI data that are either consistent or not consistent with AD, as determined by radiologists.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormalities in Neurological Examination</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>Number of participants with abnormalities in neurological examinations as determined by the investigators. Neurological examinations included Mental Status, Speech, Cranial Nerves (including pupil equality and reactivity), Visual field, Sensory, Motor, Coordination, Gait, Primitive reflexes, Tendon reflexes and Romberg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-a-beta IgG Titer at Specified Visits</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>Geometric mean of anti-a-beta IgG titer from pre-study through Week 104</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-a-beta IgM Titer at Specified Visits</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>Geotmetric mean of anti-a-beta IgM titer from pre-study through Week 104</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The Mean Changes in Alzheimer's Disease Assessment Scale-Cognitive Behavior (ADAS-Cog) Score From Baseline at Week 12, 26, 52, 78 and 104.</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>The ADAS-Cog is a 12-item,objective measure of cognitive function, consisting of 1) Word Recall, 2) Naming Objects and Fingers, 3) Following Commands, 4) Constructional Praxis, 5) Ideational Praxis, 6) Orientation, 7) Word Recognition, 8) Recall of Test Instructions, 9) Spoken Language Ability, 10) Word-Finding Difficulty, 11) Comprehension of Spoken Language and 12) Concentration/Distractibility. For this study, the ADAS-Cog total score is derived by summing the individual scores from items 1 to 11. Total score ranges from 0 to 70 points, with higher scores indicating a greater degree of impairment.</description>
  </other_outcome>
  <other_outcome>
    <measure>The Mean Changes in Disability Assessment for Dementia (DAD) Score From Baseline at Week 12, 26, 52,78 and 104.</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>The DAD is administered through an interview with the caregiver and measures instrumental and basic activities of daily living.
A total score is obtained by adding the rating for each question and converting this total score out of 100. Higher scores represent less disability in ADL while lower scores indicate more dysfunction.</description>
  </other_outcome>
  <other_outcome>
    <measure>The Mean Changes in Neuropsychological Test Battery (NTB) Score From Baseline at Week 12, 26, 52 and 78.</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>The NTB is a composite of nine widely used neuropsychological tests that assess immediate and delayed recall of verbal and visual information, attention, verbal fluency and executive function. The cognitive tests included in the NTB are the Wechsler Memory Scale (WMS) Visual-Paired Associates (immediate and delayed), WMS-Verbal Paired Associates (immediate and delayed), Rey Auditory Verbal Learning Test (immediate and delayed), WMS-Digit Span, Controlled Word Association Test, and Category Fluency Test. The NTB z-score is used for analysis. The z-score for each component is calculated through the following formula: z = (y_visit - y_base)/SD_base, where y_visit is a value at a particular time point and y_base is the average test score, and SD_base is the SD based on all participants' observed baseline scores in the study.</description>
  </other_outcome>
  <other_outcome>
    <measure>The Mean Changes in Mini-Mental State Examination (MMSE) Score From Baseline at Week 4, 8, 12, 16, 26, 30, 40, 52, 78 and 104.</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>The MMSE is a brief, structured examination of cognitive function. It has a total score of 30 points (0-30), and any score equal to or lower than 26 points indicates cognitive impairment.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>ACC-001 + QS-21</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active vaccine + adjuvant, IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QS-21</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Adjuvant, IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACC-001</intervention_name>
    <description>IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12</description>
    <arm_group_label>ACC-001 + QS-21</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>QS-21</intervention_name>
    <description>IM injection, dose of 50 micrograms, at Day 1, month 1, 3, 6 and 12</description>
    <arm_group_label>ACC-001 + QS-21</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>QS-21</intervention_name>
    <description>IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12</description>
    <arm_group_label>QS-21</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of mild to moderate Alzheimer's Disease

          -  Mini-Mental State Examination (MMSE) 16-26

        Exclusion Criteria:

          -  Significant Neurological Disease other than Alzheimer's disease

          -  Major psychiatric disorder

          -  Clinically significant systemic illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Meitetsu Hospital</name>
      <address>
        <city>Aichi</city>
        <zip>451-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ibaraki Prefectural Central Hospital</name>
      <address>
        <city>Ibaraki</city>
        <zip>309-1793</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan Atsugi Hospital</name>
      <address>
        <city>Kanagawa</city>
        <zip>243-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitasato University East Hospital</name>
      <address>
        <city>Kanagawa</city>
        <zip>252-0380</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tazuke Kofukai Medical Research Institute Kitano Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>530-8480</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jikei University School of medicine</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo Tokyo Koto Geriatric Medical Center</name>
      <address>
        <city>Tokyo</city>
        <zip>136-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanto Ctrl Hp of the Mutual Aid Asso of Public school Teache</name>
      <address>
        <city>Tokyo</city>
        <zip>158-8531</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3134K1-2206&amp;StudyName=Safety%2C%20Tolerability%2C%20And%20Immunogenicity%20Study%20Of%20ACC-001%20In%20Japanese%20Subjects%20With%20Mild%20To%20Moderate%20Alzheimer%27s%20Disease</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2009</study_first_submitted>
  <study_first_submitted_qc>August 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2009</study_first_posted>
  <results_first_submitted>May 9, 2014</results_first_submitted>
  <results_first_submitted_qc>November 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 1, 2016</results_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>QS 21</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ACC-001 3 Micrograms + QS-21</title>
          <description>A cohort of participants who received intramuscular (IM) injection of active vaccine ACC-001 (3 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
        </group>
        <group group_id="P2">
          <title>ACC-001 10 Micrograms + QS-21</title>
          <description>A cohort of participants who received IM injection of active vaccine ACC-001 (10 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
        </group>
        <group group_id="P3">
          <title>ACC-001 30 Micrograms + QS-21</title>
          <description>A cohort of participants who received IM injection of active vaccine ACC-001 (30 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
        </group>
        <group group_id="P4">
          <title>QS-21</title>
          <description>A cohort of participants who received IM injection of adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Request</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Caregiver Request</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ACC-001 3 Micrograms + QS-21</title>
          <description>A cohort of participants who received intramuscular (IM) injection of active vaccine ACC-001 (3 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
        </group>
        <group group_id="B2">
          <title>ACC-001 10 Micrograms + QS-21</title>
          <description>A cohort of participants who received IM injection of active vaccine ACC-001 (10 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
        </group>
        <group group_id="B3">
          <title>ACC-001 30 Micrograms + QS-21</title>
          <description>A cohort of participants who received IM injection of active vaccine ACC-001 (30 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
        </group>
        <group group_id="B4">
          <title>QS-21</title>
          <description>A cohort of participants who received IM injection of adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.50" spread="8.73"/>
                    <measurement group_id="B2" value="68.00" spread="10.34"/>
                    <measurement group_id="B3" value="74.33" spread="6.69"/>
                    <measurement group_id="B4" value="64.75" spread="7.15"/>
                    <measurement group_id="B5" value="69.81" spread="8.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Treatment-emergent Adverse Events (AEs) by Severity</title>
        <description>Number of participants who experienced mild, moderate, or severe AEs (mild = does not interfere with subject's usual function; moderate = interferes to some extent with subject's usual function; severe = interferes significantly with subject's usual function)</description>
        <time_frame>Baseline up to 24 months</time_frame>
        <population>The safety analysis population includes all of the randomly assigned participants who took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>ACC-001 3 Micrograms + QS-21</title>
            <description>A cohort of participants who received intramuscular (IM) injection of active vaccine ACC-001 (3 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
          <group group_id="O2">
            <title>ACC-001 10 Micrograms + QS-21</title>
            <description>A cohort of participants who received IM injection of active vaccine ACC-001 (10 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
          <group group_id="O3">
            <title>ACC-001 30 Micrograms + QS-21</title>
            <description>A cohort of participants who received IM injection of active vaccine ACC-001 (30 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
          <group group_id="O4">
            <title>QS-21</title>
            <description>A cohort of participants who received IM injection of adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Treatment-emergent Adverse Events (AEs) by Severity</title>
          <description>Number of participants who experienced mild, moderate, or severe AEs (mild = does not interfere with subject's usual function; moderate = interferes to some extent with subject's usual function; severe = interferes significantly with subject's usual function)</description>
          <population>The safety analysis population includes all of the randomly assigned participants who took at least one dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Brain Abnormalities in Magnetic Resonance Imaging (MRI) Data</title>
        <description>Number of participants with brain abnormalities in MRI data that are either consistent or not consistent with AD, as determined by radiologists.</description>
        <time_frame>Baseline up to 24 months</time_frame>
        <population>The safety analysis population includes all of the randomly assigned participants who took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>ACC-001 3 Micrograms + QS-21</title>
            <description>A cohort of participants who received intramuscular (IM) injection of active vaccine ACC-001 (3 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 3, 6, 9 and 12</description>
          </group>
          <group group_id="O2">
            <title>ACC-001 10 Micrograms + QS-21</title>
            <description>A cohort of participants who received IM injection of active vaccine ACC-001 (10 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
          <group group_id="O3">
            <title>ACC-001 30 Micrograms + QS-21</title>
            <description>A cohort of participants who received IM injection of active vaccine ACC-001 (30 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
          <group group_id="O4">
            <title>QS-21</title>
            <description>A cohort of participants who received IM injection of adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Brain Abnormalities in Magnetic Resonance Imaging (MRI) Data</title>
          <description>Number of participants with brain abnormalities in MRI data that are either consistent or not consistent with AD, as determined by radiologists.</description>
          <population>The safety analysis population includes all of the randomly assigned participants who took at least one dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal - inconsistent with AD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal - consistent with AD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormalities in Neurological Examination</title>
        <description>Number of participants with abnormalities in neurological examinations as determined by the investigators. Neurological examinations included Mental Status, Speech, Cranial Nerves (including pupil equality and reactivity), Visual field, Sensory, Motor, Coordination, Gait, Primitive reflexes, Tendon reflexes and Romberg.</description>
        <time_frame>Baseline up to 24 months</time_frame>
        <population>The safety analysis population includes all of the randomly assigned participants who took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>ACC-001 3 Micrograms + QS-21</title>
            <description>A cohort of participants who received intramuscular (IM) injection of active vaccine ACC-001 (3 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 3, 6, 9 and 12</description>
          </group>
          <group group_id="O2">
            <title>ACC-001 10 Micrograms + QS-21</title>
            <description>A cohort of participants who received IM injection of active vaccine ACC-001 (10 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
          <group group_id="O3">
            <title>ACC-001 30 Micrograms + QS-21</title>
            <description>A cohort of participants who received IM injection of active vaccine ACC-001 (30 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
          <group group_id="O4">
            <title>QS-21</title>
            <description>A cohort of participants who received IM injection of adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormalities in Neurological Examination</title>
          <description>Number of participants with abnormalities in neurological examinations as determined by the investigators. Neurological examinations included Mental Status, Speech, Cranial Nerves (including pupil equality and reactivity), Visual field, Sensory, Motor, Coordination, Gait, Primitive reflexes, Tendon reflexes and Romberg.</description>
          <population>The safety analysis population includes all of the randomly assigned participants who took at least one dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Speech</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cranial Nerves</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visual Field</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Motor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coordination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primitive reflexes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tendon reflexes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romberg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-a-beta IgG Titer at Specified Visits</title>
        <description>Geometric mean of anti-a-beta IgG titer from pre-study through Week 104</description>
        <time_frame>Baseline up to 24 months</time_frame>
        <population>The population for immunogenicity analysis includes all of the randomly assigned participants who took at least one dose of study medication, having the baseline and at least one post baseline immunogenicity evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>ACC-001 3 Micrograms + QS-21</title>
            <description>A cohort of participants who received intramuscular (IM) injection of active vaccine ACC-001 (3 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
          <group group_id="O2">
            <title>ACC-001 10 Micrograms + QS-21</title>
            <description>A cohort of participants who received IM injection of active vaccine ACC-001 (10 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
          <group group_id="O3">
            <title>ACC-001 30 Micrograms + QS-21</title>
            <description>A cohort of participants who received IM injection of active vaccine ACC-001 (30 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
          <group group_id="O4">
            <title>QS-21</title>
            <description>A cohort of participants who received IM injection of adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-a-beta IgG Titer at Specified Visits</title>
          <description>Geometric mean of anti-a-beta IgG titer from pre-study through Week 104</description>
          <population>The population for immunogenicity analysis includes all of the randomly assigned participants who took at least one dose of study medication, having the baseline and at least one post baseline immunogenicity evaluation.</population>
          <units>Units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-study (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O2" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O3" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.2" lower_limit="35.5" upper_limit="109.3"/>
                    <measurement group_id="O2" value="65.0" lower_limit="35.5" upper_limit="118.9"/>
                    <measurement group_id="O3" value="67.0" lower_limit="34.1" upper_limit="131.8"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.9" lower_limit="30.3" upper_limit="384.4"/>
                    <measurement group_id="O2" value="94.2" lower_limit="40.1" upper_limit="221.1"/>
                    <measurement group_id="O3" value="79.0" lower_limit="27.5" upper_limit="227.1"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2106.5" lower_limit="141.7" upper_limit="31312.7"/>
                    <measurement group_id="O2" value="4793.2" lower_limit="1261.0" upper_limit="18220.0"/>
                    <measurement group_id="O3" value="5702.6" lower_limit="1181.1" upper_limit="17288.0"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1143.3" lower_limit="108.0" upper_limit="12104.3"/>
                    <measurement group_id="O2" value="2331.4" lower_limit="512.2" upper_limit="10612.3"/>
                    <measurement group_id="O3" value="3423.9" lower_limit="1182.1" upper_limit="9917.0"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="979.2" lower_limit="96.8" upper_limit="9903.1"/>
                    <measurement group_id="O2" value="1674.9" lower_limit="369.5" upper_limit="7592.9"/>
                    <measurement group_id="O3" value="2012.4" lower_limit="643.4" upper_limit="6294.9"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6088.4" lower_limit="714.5" upper_limit="51878.2"/>
                    <measurement group_id="O2" value="6286.2" lower_limit="3923.5" upper_limit="10071.6"/>
                    <measurement group_id="O3" value="9983.5" lower_limit="2820.9" upper_limit="35333.3"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3860.4" lower_limit="342.5" upper_limit="43507.1"/>
                    <measurement group_id="O2" value="4170.4" lower_limit="2641.8" upper_limit="6583.4"/>
                    <measurement group_id="O3" value="9228.0" lower_limit="2930.5" upper_limit="29058.2"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1151.5" lower_limit="165.8" upper_limit="7998.4"/>
                    <measurement group_id="O2" value="1455.0" lower_limit="936.2" upper_limit="2261.1"/>
                    <measurement group_id="O3" value="3903.1" lower_limit="1151.8" upper_limit="13226.8"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=6,9,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8216.5" lower_limit="1550.5" upper_limit="43541.2"/>
                    <measurement group_id="O2" value="8929.3" lower_limit="4466.9" upper_limit="17849.8"/>
                    <measurement group_id="O3" value="7429.5" lower_limit="3925.7" upper_limit="14060.5"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 (n=6,9,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7218.7" lower_limit="1438.9" upper_limit="36213.5"/>
                    <measurement group_id="O2" value="7017.4" lower_limit="3510.7" upper_limit="14026.7"/>
                    <measurement group_id="O3" value="6162.2" lower_limit="3062.2" upper_limit="12400.6"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=5,9,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3136.4" lower_limit="651.2" upper_limit="15106.7"/>
                    <measurement group_id="O2" value="2706.5" lower_limit="1358.1" upper_limit="5393.9"/>
                    <measurement group_id="O3" value="3615.5" lower_limit="1145.5" upper_limit="11411.2"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50 (n=6,8,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1854.5" lower_limit="558.3" upper_limit="6159.4"/>
                    <measurement group_id="O2" value="1255.8" lower_limit="656.3" upper_limit="2402.9"/>
                    <measurement group_id="O3" value="1261.4" lower_limit="699.2" upper_limit="2275.9"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54 (n=5,8,7,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2873.6" lower_limit="264.8" upper_limit="31178.1"/>
                    <measurement group_id="O2" value="9636.4" lower_limit="4558.5" upper_limit="20370.7"/>
                    <measurement group_id="O3" value="8604.6" lower_limit="4030.7" upper_limit="18368.8"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56 (n=4,8,7,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11006.2" lower_limit="1617.8" upper_limit="74878.3"/>
                    <measurement group_id="O2" value="7582.4" lower_limit="3143.9" upper_limit="18286.8"/>
                    <measurement group_id="O3" value="6201.5" lower_limit="2921.4" upper_limit="13164.5"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 66 (n=4,8,7,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7407.9" lower_limit="1127.0" upper_limit="48693.5"/>
                    <measurement group_id="O2" value="3942.5" lower_limit="1539.4" upper_limit="10096.9"/>
                    <measurement group_id="O3" value="2452.5" lower_limit="1442.5" upper_limit="4169.7"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78 (n=4,8,6,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5108.6" lower_limit="1013.9" upper_limit="25739.1"/>
                    <measurement group_id="O2" value="2465.3" lower_limit="961.9" upper_limit="6318.5"/>
                    <measurement group_id="O3" value="1316.3" lower_limit="645.0" upper_limit="2686.1"/>
                    <measurement group_id="O4" value="50.0" lower_limit="50.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 91 (n=0,1,1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O2" value="546.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O3" value="389.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O4" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 (n=0,1,1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O2" value="414.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O3" value="285.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O4" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-a-beta IgM Titer at Specified Visits</title>
        <description>Geotmetric mean of anti-a-beta IgM titer from pre-study through Week 104</description>
        <time_frame>Baseline up to 24 months</time_frame>
        <population>The population for immunogenicity analysis includes all of the randomly assigned participants who took at least one dose of study medication, having the baseline and at least one post baseline immunogenicity evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>ACC-001 3 Micrograms + QS-21</title>
            <description>A cohort of participants who received intramuscular (IM) injection of active vaccine ACC-001 (3 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 3, 6, 9 and 12</description>
          </group>
          <group group_id="O2">
            <title>ACC-001 10 Micrograms + QS-21</title>
            <description>A cohort of participants who received IM injection of active vaccine ACC-001 (10 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
          <group group_id="O3">
            <title>ACC-001 30 Micrograms + QS-21</title>
            <description>A cohort of participants who received IM injection of active vaccine ACC-001 (30 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
          <group group_id="O4">
            <title>QS-21</title>
            <description>A cohort of participants who received IM injection of adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-a-beta IgM Titer at Specified Visits</title>
          <description>Geotmetric mean of anti-a-beta IgM titer from pre-study through Week 104</description>
          <population>The population for immunogenicity analysis includes all of the randomly assigned participants who took at least one dose of study medication, having the baseline and at least one post baseline immunogenicity evaluation.</population>
          <units>Units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-study (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9" lower_limit="17.9" upper_limit="53.6"/>
                    <measurement group_id="O2" value="28.2" lower_limit="21.3" upper_limit="37.4"/>
                    <measurement group_id="O3" value="25.0" lower_limit="25.0" upper_limit="25.0"/>
                    <measurement group_id="O4" value="41.5" lower_limit="21.8" upper_limit="78.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1" lower_limit="17.1" upper_limit="347.0"/>
                    <measurement group_id="O2" value="92.0" lower_limit="31.7" upper_limit="266.6"/>
                    <measurement group_id="O3" value="53.5" lower_limit="22.5" upper_limit="127.6"/>
                    <measurement group_id="O4" value="42.4" lower_limit="21.6" upper_limit="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.5" lower_limit="19.4" upper_limit="605.6"/>
                    <measurement group_id="O2" value="141.5" lower_limit="41.6" upper_limit="481.5"/>
                    <measurement group_id="O3" value="108.5" lower_limit="41.0" upper_limit="286.9"/>
                    <measurement group_id="O4" value="43.7" lower_limit="21.6" upper_limit="88.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="953.2" lower_limit="95.7" upper_limit="9493.1"/>
                    <measurement group_id="O2" value="2988.4" lower_limit="879.2" upper_limit="10157.9"/>
                    <measurement group_id="O3" value="2381.4" lower_limit="662.7" upper_limit="8556.9"/>
                    <measurement group_id="O4" value="43.0" lower_limit="21.6" upper_limit="85.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="848.6" lower_limit="85.6" upper_limit="8414.6"/>
                    <measurement group_id="O2" value="2940.1" lower_limit="812.5" upper_limit="10639.6"/>
                    <measurement group_id="O3" value="2776.2" lower_limit="622.2" upper_limit="12386.2"/>
                    <measurement group_id="O4" value="46.9" lower_limit="23.7" upper_limit="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="850.8" lower_limit="147.5" upper_limit="4907.8"/>
                    <measurement group_id="O2" value="2432.1" lower_limit="661.4" upper_limit="8943.5"/>
                    <measurement group_id="O3" value="2323.9" lower_limit="482.5" upper_limit="11192.7"/>
                    <measurement group_id="O4" value="36.1" lower_limit="19.1" upper_limit="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1487.6" lower_limit="288.1" upper_limit="7682.0"/>
                    <measurement group_id="O2" value="2231.0" lower_limit="728.6" upper_limit="6831.2"/>
                    <measurement group_id="O3" value="4438.5" lower_limit="1000.5" upper_limit="19689.6"/>
                    <measurement group_id="O4" value="37.6" lower_limit="19.6" upper_limit="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1503.2" lower_limit="254.5" upper_limit="8880.8"/>
                    <measurement group_id="O2" value="2484.8" lower_limit="797.6" upper_limit="7740.9"/>
                    <measurement group_id="O3" value="4590.6" lower_limit="1041.7" upper_limit="20230.3"/>
                    <measurement group_id="O4" value="40.5" lower_limit="18.4" upper_limit="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="898.5" lower_limit="222.1" upper_limit="3634.1"/>
                    <measurement group_id="O2" value="1421.8" lower_limit="442.7" upper_limit="4565.8"/>
                    <measurement group_id="O3" value="2396.4" lower_limit="643.2" upper_limit="8928.8"/>
                    <measurement group_id="O4" value="40.1" lower_limit="18.4" upper_limit="87.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=6,9,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="885.9" lower_limit="240.0" upper_limit="3270.2"/>
                    <measurement group_id="O2" value="3395.8" lower_limit="1356.5" upper_limit="8500.9"/>
                    <measurement group_id="O3" value="3592.8" lower_limit="628.7" upper_limit="20531.3"/>
                    <measurement group_id="O4" value="42.1" lower_limit="21.3" upper_limit="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 (n=6,9,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="859.5" lower_limit="273.2" upper_limit="2704.0"/>
                    <measurement group_id="O2" value="3729.9" lower_limit="1286.6" upper_limit="10812.9"/>
                    <measurement group_id="O3" value="2956.7" lower_limit="636.6" upper_limit="13732.9"/>
                    <measurement group_id="O4" value="38.9" lower_limit="19.4" upper_limit="78.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=5,9,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="449.0" lower_limit="110.4" upper_limit="1825.7"/>
                    <measurement group_id="O2" value="2480.5" lower_limit="760.2" upper_limit="8093.8"/>
                    <measurement group_id="O3" value="1967.3" lower_limit="421.5" upper_limit="9183.1"/>
                    <measurement group_id="O4" value="37.8" lower_limit="19.2" upper_limit="74.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50 (n=6,8,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354.2" lower_limit="75.6" upper_limit="1659.4"/>
                    <measurement group_id="O2" value="1330.0" lower_limit="388.5" upper_limit="4553.3"/>
                    <measurement group_id="O3" value="1326.8" lower_limit="233.3" upper_limit="7546.2"/>
                    <measurement group_id="O4" value="39.9" lower_limit="17.9" upper_limit="88.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54 (n=5,8,7,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="680.7" lower_limit="120.0" upper_limit="3861.3"/>
                    <measurement group_id="O2" value="2605.4" lower_limit="862.1" upper_limit="7874.2"/>
                    <measurement group_id="O3" value="3017.0" lower_limit="678.8" upper_limit="13408.9"/>
                    <measurement group_id="O4" value="48.3" lower_limit="19.2" upper_limit="121.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56 (n=4,8,7,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1768.3" lower_limit="342.4" upper_limit="9132.4"/>
                    <measurement group_id="O2" value="2570.6" lower_limit="794.2" upper_limit="8320.4"/>
                    <measurement group_id="O3" value="3051.9" lower_limit="618.2" upper_limit="15066.0"/>
                    <measurement group_id="O4" value="40.5" lower_limit="16.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 66 (n=4,8,7,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1213.0" lower_limit="244.1" upper_limit="6027.2"/>
                    <measurement group_id="O2" value="1872.7" lower_limit="523.3" upper_limit="6701.7"/>
                    <measurement group_id="O3" value="1825.1" lower_limit="346.2" upper_limit="9621.6"/>
                    <measurement group_id="O4" value="46.0" lower_limit="20.2" upper_limit="104.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78 (n=4,8,6,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="952.8" lower_limit="251.0" upper_limit="3617.1"/>
                    <measurement group_id="O2" value="1650.3" lower_limit="491.4" upper_limit="5542.5"/>
                    <measurement group_id="O3" value="844.9" lower_limit="155.4" upper_limit="4594.7"/>
                    <measurement group_id="O4" value="48.3" lower_limit="19.0" upper_limit="122.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 91 (n=0,1,1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O2" value="219.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O3" value="351.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O4" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 (n=0,1,1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O2" value="154.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O3" value="258.0">95% confidence interval was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O4" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Mean Changes in Alzheimer's Disease Assessment Scale-Cognitive Behavior (ADAS-Cog) Score From Baseline at Week 12, 26, 52, 78 and 104.</title>
        <description>The ADAS-Cog is a 12-item,objective measure of cognitive function, consisting of 1) Word Recall, 2) Naming Objects and Fingers, 3) Following Commands, 4) Constructional Praxis, 5) Ideational Praxis, 6) Orientation, 7) Word Recognition, 8) Recall of Test Instructions, 9) Spoken Language Ability, 10) Word-Finding Difficulty, 11) Comprehension of Spoken Language and 12) Concentration/Distractibility. For this study, the ADAS-Cog total score is derived by summing the individual scores from items 1 to 11. Total score ranges from 0 to 70 points, with higher scores indicating a greater degree of impairment.</description>
        <time_frame>Baseline up to 24 months</time_frame>
        <population>Efficacy analyses were performed on the modified intent-to-treat (mITT) population. The mITT population included all of the randomly assigned participants who took at least one dose of study medication, and had the baseline and at least one post baseline evaluation of the key efficacy variable (ADAS-Cog).</population>
        <group_list>
          <group group_id="O1">
            <title>ACC-001 3 Micrograms + QS-21</title>
            <description>A cohort of participants who received intramuscular (IM) injection of active vaccine ACC-001 (3 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
          <group group_id="O2">
            <title>ACC-001 10 Micrograms + QS-21</title>
            <description>A cohort of participants who received IM injection of active vaccine ACC-001 (10 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
          <group group_id="O3">
            <title>ACC-001 30 Micrograms + QS-21</title>
            <description>A cohort of participants who received IM injection of active vaccine ACC-001 (30 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
          <group group_id="O4">
            <title>QS-21</title>
            <description>A cohort of participants who received IM injection of adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Changes in Alzheimer's Disease Assessment Scale-Cognitive Behavior (ADAS-Cog) Score From Baseline at Week 12, 26, 52, 78 and 104.</title>
          <description>The ADAS-Cog is a 12-item,objective measure of cognitive function, consisting of 1) Word Recall, 2) Naming Objects and Fingers, 3) Following Commands, 4) Constructional Praxis, 5) Ideational Praxis, 6) Orientation, 7) Word Recognition, 8) Recall of Test Instructions, 9) Spoken Language Ability, 10) Word-Finding Difficulty, 11) Comprehension of Spoken Language and 12) Concentration/Distractibility. For this study, the ADAS-Cog total score is derived by summing the individual scores from items 1 to 11. Total score ranges from 0 to 70 points, with higher scores indicating a greater degree of impairment.</description>
          <population>Efficacy analyses were performed on the modified intent-to-treat (mITT) population. The mITT population included all of the randomly assigned participants who took at least one dose of study medication, and had the baseline and at least one post baseline evaluation of the key efficacy variable (ADAS-Cog).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="5.20"/>
                    <measurement group_id="O2" value="0.52" spread="4.39"/>
                    <measurement group_id="O3" value="2.93" spread="4.10"/>
                    <measurement group_id="O4" value="-0.25" spread="3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="4.38"/>
                    <measurement group_id="O2" value="-0.41" spread="5.41"/>
                    <measurement group_id="O3" value="3.56" spread="6.74"/>
                    <measurement group_id="O4" value="-0.63" spread="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=5,9,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="8.32"/>
                    <measurement group_id="O2" value="0.15" spread="4.82"/>
                    <measurement group_id="O3" value="5.05" spread="6.68"/>
                    <measurement group_id="O4" value="1.04" spread="7.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78 (n=4,8,6,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="3.50"/>
                    <measurement group_id="O2" value="3.40" spread="7.08"/>
                    <measurement group_id="O3" value="5.39" spread="3.66"/>
                    <measurement group_id="O4" value="2.33" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 (n=0,1,1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O2" value="-4.33">Standard deviation was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O3" value="8.33">Standard deviation was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O4" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Mean Changes in Disability Assessment for Dementia (DAD) Score From Baseline at Week 12, 26, 52,78 and 104.</title>
        <description>The DAD is administered through an interview with the caregiver and measures instrumental and basic activities of daily living.
A total score is obtained by adding the rating for each question and converting this total score out of 100. Higher scores represent less disability in ADL while lower scores indicate more dysfunction.</description>
        <time_frame>Baseline up to 24 months</time_frame>
        <population>Efficacy analyses were performed on the modified intent-to-treat (mITT) population. The mITT population included all of the randomly assigned participants who took at least one dose of study medication, and had the baseline and at least one post baseline evaluation of the key efficacy variable (ADAS-Cog).</population>
        <group_list>
          <group group_id="O1">
            <title>ACC-001 3 Micrograms + QS-21</title>
            <description>A cohort of participants who received intramuscular (IM) injection of active vaccine ACC-001 (3 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 3, 6, 9 and 12</description>
          </group>
          <group group_id="O2">
            <title>ACC-001 10 Micrograms + QS-21</title>
            <description>A cohort of participants who received IM injection of active vaccine ACC-001 (10 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
          <group group_id="O3">
            <title>ACC-001 30 Micrograms + QS-21</title>
            <description>A cohort of participants who received IM injection of active vaccine ACC-001 (30 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
          <group group_id="O4">
            <title>QS-21</title>
            <description>A cohort of participants who received IM injection of adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Changes in Disability Assessment for Dementia (DAD) Score From Baseline at Week 12, 26, 52,78 and 104.</title>
          <description>The DAD is administered through an interview with the caregiver and measures instrumental and basic activities of daily living.
A total score is obtained by adding the rating for each question and converting this total score out of 100. Higher scores represent less disability in ADL while lower scores indicate more dysfunction.</description>
          <population>Efficacy analyses were performed on the modified intent-to-treat (mITT) population. The mITT population included all of the randomly assigned participants who took at least one dose of study medication, and had the baseline and at least one post baseline evaluation of the key efficacy variable (ADAS-Cog).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=5,9,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="9.7"/>
                    <measurement group_id="O2" value="0.7" spread="2.6"/>
                    <measurement group_id="O3" value="1.5" spread="5.1"/>
                    <measurement group_id="O4" value="1.7" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=6,9,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="14.5"/>
                    <measurement group_id="O2" value="-0.2" spread="11.9"/>
                    <measurement group_id="O3" value="-4.4" spread="28.6"/>
                    <measurement group_id="O4" value="-0.6" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=5,8,6,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.2" spread="20.9"/>
                    <measurement group_id="O2" value="-3.4" spread="10.7"/>
                    <measurement group_id="O3" value="-1.8" spread="5.1"/>
                    <measurement group_id="O4" value="-3.1" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78 (n=4,8,5,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="3.1"/>
                    <measurement group_id="O2" value="-5.4" spread="7.7"/>
                    <measurement group_id="O3" value="0.5" spread="6.9"/>
                    <measurement group_id="O4" value="3.5" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 (n=0,1,1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O2" value="0">Standard deviation was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O3" value="12.8">Standard deviation was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O4" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Mean Changes in Neuropsychological Test Battery (NTB) Score From Baseline at Week 12, 26, 52 and 78.</title>
        <description>The NTB is a composite of nine widely used neuropsychological tests that assess immediate and delayed recall of verbal and visual information, attention, verbal fluency and executive function. The cognitive tests included in the NTB are the Wechsler Memory Scale (WMS) Visual-Paired Associates (immediate and delayed), WMS-Verbal Paired Associates (immediate and delayed), Rey Auditory Verbal Learning Test (immediate and delayed), WMS-Digit Span, Controlled Word Association Test, and Category Fluency Test. The NTB z-score is used for analysis. The z-score for each component is calculated through the following formula: z = (y_visit  y_base)/SD_base, where y_visit is a value at a particular time point and y_base is the average test score, and SD_base is the SD based on all participants observed baseline scores in the study.</description>
        <time_frame>Baseline up to 24 months</time_frame>
        <population>Efficacy analyses were performed on the modified intent-to-treat (mITT) population. The mITT population included all of the randomly assigned participants who took at least one dose of study medication, and had the baseline and at least one post baseline evaluation of the key efficacy variable (ADAS-Cog).</population>
        <group_list>
          <group group_id="O1">
            <title>ACC-001 3 Micrograms + QS-21</title>
            <description>A cohort of participants who received intramuscular (IM) injection of active vaccine ACC-001 (3 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 3, 6, 9 and 12</description>
          </group>
          <group group_id="O2">
            <title>ACC-001 10 Micrograms + QS-21</title>
            <description>A cohort of participants who received IM injection of active vaccine ACC-001 (10 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
          <group group_id="O3">
            <title>ACC-001 30 Micrograms + QS-21</title>
            <description>A cohort of participants who received IM injection of active vaccine ACC-001 (30 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
          <group group_id="O4">
            <title>QS-21</title>
            <description>A cohort of participants who received IM injection of adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Changes in Neuropsychological Test Battery (NTB) Score From Baseline at Week 12, 26, 52 and 78.</title>
          <description>The NTB is a composite of nine widely used neuropsychological tests that assess immediate and delayed recall of verbal and visual information, attention, verbal fluency and executive function. The cognitive tests included in the NTB are the Wechsler Memory Scale (WMS) Visual-Paired Associates (immediate and delayed), WMS-Verbal Paired Associates (immediate and delayed), Rey Auditory Verbal Learning Test (immediate and delayed), WMS-Digit Span, Controlled Word Association Test, and Category Fluency Test. The NTB z-score is used for analysis. The z-score for each component is calculated through the following formula: z = (y_visit  y_base)/SD_base, where y_visit is a value at a particular time point and y_base is the average test score, and SD_base is the SD based on all participants observed baseline scores in the study.</description>
          <population>Efficacy analyses were performed on the modified intent-to-treat (mITT) population. The mITT population included all of the randomly assigned participants who took at least one dose of study medication, and had the baseline and at least one post baseline evaluation of the key efficacy variable (ADAS-Cog).</population>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=6,9,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.023" spread="0.416"/>
                    <measurement group_id="O2" value="0.275" spread="0.280"/>
                    <measurement group_id="O3" value="-0.028" spread="0.282"/>
                    <measurement group_id="O4" value="0.227" spread="0.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.114" spread="0.423"/>
                    <measurement group_id="O2" value="0.254" spread="0.353"/>
                    <measurement group_id="O3" value="-0.081" spread="0.530"/>
                    <measurement group_id="O4" value="0.222" spread="0.308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=5,9,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.081" spread="0.288"/>
                    <measurement group_id="O2" value="0.211" spread="0.285"/>
                    <measurement group_id="O3" value="-0.109" spread="0.263"/>
                    <measurement group_id="O4" value="0.213" spread="0.416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78 (n=4,8,6,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.088" spread="0.334"/>
                    <measurement group_id="O2" value="-0.037" spread="0.494"/>
                    <measurement group_id="O3" value="-0.120" spread="0.442"/>
                    <measurement group_id="O4" value="0.246" spread="0.336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 (n=0,1,1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O2" value="0.514">Standard deviation was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O3" value="-0.559">Standard deviation was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O4" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Mean Changes in Mini-Mental State Examination (MMSE) Score From Baseline at Week 4, 8, 12, 16, 26, 30, 40, 52, 78 and 104.</title>
        <description>The MMSE is a brief, structured examination of cognitive function. It has a total score of 30 points (0-30), and any score equal to or lower than 26 points indicates cognitive impairment.</description>
        <time_frame>Baseline up to 24 months</time_frame>
        <population>Efficacy analyses were performed on the modified intent-to-treat (mITT) population. The mITT population included all of the randomly assigned participants who took at least one dose of study medication, and had the baseline and at least one post baseline evaluation of the key efficacy variable (ADAS-Cog).</population>
        <group_list>
          <group group_id="O1">
            <title>ACC-001 3 Micrograms + QS-21</title>
            <description>A cohort of participants who received intramuscular (IM) injection of active vaccine ACC-001 (3 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 3, 6, 9 and 12</description>
          </group>
          <group group_id="O2">
            <title>ACC-001 10 Micrograms + QS-21</title>
            <description>A cohort of participants who received IM injection of active vaccine ACC-001 (10 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
          <group group_id="O3">
            <title>ACC-001 30 Micrograms + QS-21</title>
            <description>A cohort of participants who received IM injection of active vaccine ACC-001 (30 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
          <group group_id="O4">
            <title>QS-21</title>
            <description>A cohort of participants who received IM injection of adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Changes in Mini-Mental State Examination (MMSE) Score From Baseline at Week 4, 8, 12, 16, 26, 30, 40, 52, 78 and 104.</title>
          <description>The MMSE is a brief, structured examination of cognitive function. It has a total score of 30 points (0-30), and any score equal to or lower than 26 points indicates cognitive impairment.</description>
          <population>Efficacy analyses were performed on the modified intent-to-treat (mITT) population. The mITT population included all of the randomly assigned participants who took at least one dose of study medication, and had the baseline and at least one post baseline evaluation of the key efficacy variable (ADAS-Cog).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.5"/>
                    <measurement group_id="O2" value="1.3" spread="1.7"/>
                    <measurement group_id="O3" value="1.6" spread="2.7"/>
                    <measurement group_id="O4" value="0.4" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="3.1"/>
                    <measurement group_id="O2" value="0.9" spread="3.2"/>
                    <measurement group_id="O3" value="1.3" spread="1.7"/>
                    <measurement group_id="O4" value="0.9" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="2.8"/>
                    <measurement group_id="O2" value="1.1" spread="2.7"/>
                    <measurement group_id="O3" value="1.1" spread="2.0"/>
                    <measurement group_id="O4" value="1.4" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=6,9,9,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="3.4"/>
                    <measurement group_id="O2" value="1.3" spread="2.3"/>
                    <measurement group_id="O3" value="2.9" spread="2.5"/>
                    <measurement group_id="O4" value="0.4" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=6,9,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="3.8"/>
                    <measurement group_id="O2" value="0.1" spread="2.6"/>
                    <measurement group_id="O3" value="1.0" spread="2.8"/>
                    <measurement group_id="O4" value="-0.1" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 (n=6,9,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="3.7"/>
                    <measurement group_id="O2" value="1.2" spread="2.4"/>
                    <measurement group_id="O3" value="1.6" spread="2.4"/>
                    <measurement group_id="O4" value="0.3" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=4,9,7,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="2.2"/>
                    <measurement group_id="O2" value="0.8" spread="3.5"/>
                    <measurement group_id="O3" value="0.7" spread="2.0"/>
                    <measurement group_id="O4" value="0.5" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=5,8,7,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="4.5"/>
                    <measurement group_id="O2" value="1.0" spread="3.8"/>
                    <measurement group_id="O3" value="1.1" spread="2.1"/>
                    <measurement group_id="O4" value="0.6" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78 (n=4,8,6,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="2.5"/>
                    <measurement group_id="O2" value="-1.4" spread="3.9"/>
                    <measurement group_id="O3" value="-0.3" spread="1.2"/>
                    <measurement group_id="O4" value="0.0" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 (n=0,1,1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                    <measurement group_id="O2" value="-2.0">Standard deviation was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O3" value="-1.0">Standard deviation was not estimable since only one participant was evaluable.</measurement>
                    <measurement group_id="O4" value="NA">Data were not analyzed as no participants were evaluable for the particular week.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>ACC-001 3 Micrograms + QS-21</title>
          <description>A cohort of participants who received intramuscular (IM) injection of active vaccine ACC-001 (3 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
        </group>
        <group group_id="E2">
          <title>ACC-001 10 Micrograms + QS-21</title>
          <description>A cohort of participants who received IM injection of active vaccine ACC-001 (10 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
        </group>
        <group group_id="E3">
          <title>ACC-001 30 Micrograms + QS-21</title>
          <description>A cohort of participants who received IM injection of active vaccine ACC-001 (30 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
        </group>
        <group group_id="E4">
          <title>QS-21</title>
          <description>A cohort of participants who received IM injection of adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Chillblains</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Positive Rombergism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Lipid metabolism disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Cerebral microhaemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Meralgia paraesthetica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

